Direct Pan-Cancer Multi-Omic Analysis of Radiotherapy Response Reveals Coding and Regulatory Genomic Variation, and Extracellular Adaptive Programs Underlying Radioresistance
En palabras de los autores
Radioresistance remains a major barrier to effective radiotherapy, yet its molecular determinants remain incompletely understood. Most radiogenomic studies infer radioresistance using surrogate endpoints rather than from clinically annotated treatment response data. Here, we analysed genomic, transcriptomic, immune and clinical features of 1,445 radiotherapy-treated patients across 15 cancer types represented in The Cancer Genome Atlas with documented radiotherapy outcomes. Cancer-type-specific somatic association analyses identified 132 significant candidate variant associations across six cancer types, including three previously unannotated coding variants in TCF20, PTPN14, and CADM1. Functional annotation showed that radioresistant tumours were enriched for cytoplasmic, protein-associated, and metabolic functions, whereas radiosensitive tumours were enriched for nuclear regulatory programs. Through transcriptomic analysis, we identified 107 differentially expressed genes across 8 cancer types, enriched for extracellular signalling, secretory programs, and tumour microenvironment interactions. The genomic and transcriptomic analyses revealed a limited gene overlap but converged on cellular adaptation and survival. Together, our findings suggest that radioresistance is characterised by complementary adaptive processes, whereby intracellular protein-regulatory and metabolic processes are coupled with extracellular signalling and tumour microenvironment interactions. Clinically, radioresistance was associated with significantly poorer overall survival, whereas the radiosensitivity index and inferred tumour immune composition showed limited concordance with observed treatment response. To our knowledge, this study provides the first pan-cancer characterisation of clinically defined radiotherapy response and identifies potential candidate biomarkers for functional validation.
En palabras simples Resumen con IA
Los investigadores estudiaron 1,445 pacientes con cáncer de 15 tipos que recibieron radioterapia y tenían resultados documentados. Encontraron 132 variantes genéticas vinculadas a la radioresistencia en seis tipos de cáncer, incluyendo tres variantes nuevas en TCF20, PTPN14 y CADM1. Los tumores radioresistentes mostraron más funciones metabólicas y de proteínas, mientras que los tumores radiosensibles mostraron más programas de control nuclear. También encontraron 107 genes con actividad diferente en ocho tipos de cáncer, relacionados con señales fuera de las células e interacciones del entorno tumoral. La radioresistencia se vinculó a una supervivencia significativamente peor, pero la composición inmune y el índice de sensibilidad no coincidieron bien con la respuesta real al tratamiento.
Escrito por Kimi K2.5 usando solo el abstract de arriba. Jev verificó que cada oración esté respaldada por las oraciones del abstract que cita y eliminó las que no. Pasá el cursor por una oración para ver de dónde sale.
Apareció: sábado, 26 de septiembre. medRxiv. Preprint, todavía sin revisión por pares.